Limitless X Holdings director Michael Braun to resign June 30

Aardvark reported exploratory data from the ARD-101 trial, showing reductions in hyperphagia scores. The FDA lifted the clinical hold on ARD-101, and the company plans to seek FDA input on a new Phase 3 trial, expecting to resume clinical activities in 2027. The trial showed modest efficacy and was generally well tolerated.

SpaceX is reportedly in talks to access 80,000 U.S. cell sites, potentially becoming a fourth wireless carrier. Crown Castle and American Tower saw after-hours gains, while carriers like Verizon, AT&T, and T-Mobile lost earlier gains. SpaceX's stock rose slightly after a daytime drop. No lease has been signed, and details remain uncertain. Analysts estimate a nationwide network could cost over $80 billion.

BriaCell Therapeutics (BCTX) reported biomarker study results showing CAML PD-L1 expression linked to survival in metastatic breast cancer patients treated with immunotherapy. The study involved 111 patients and various treatments, including BriaCell's Bria-IMT regimen. BCTX stock rose 5.88% in pre-market trading to $3.61.

Globe Life (GL) shares fell 3.4% to $162.69 in pre-market trading after Piper Sandler downgraded the stock to Neutral from Overweight, lowering the price target to $165 from $200.

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials • HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory • HQ-CT scores fell by Week 2 of dose escala

Stifel reiterated a Buy rating for TTM Technologies with a $165 price target, suggesting 123.3% upside. The company reported 60% revenue growth in 3Q26, reaching $1.20 billion, and an adjusted EPS of $1.46, driven by strong demand in Aerospace & Defense and Medical Industrial sectors.